Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Brii Biosciences Limited (2137.HK)
Beijing, CN
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -4.96% | -14.81% | -26.28% | -33.91% | -18.44% | -37.50% | -69.41% | -94.99% | -94.99% | -94.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-66.6% Q4'25: +12.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+57.1% ★ Q4'25: -580.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,983.4% Q4'25: -577.7% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-1,632.6% Q4'25: -664.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-75.6% Q4'25: -124.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-1.2% ★ Q4'25: -1.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q4'25: -0.02× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
51.63M
est: 161.02M (-67.9%)
|
56.32M
est: 35.70M (+57.8%)
|
54.29M
est: -77.47M (+170.1%)
|
18.12M
est: 28.29M (-35.9%)
|
310.76M
310.76M – 310.76M
+998.6% YoY
|
435.09M
435.09M – 435.09M
+40.0% YoY
|
2.17B
2.17B – 2.17B
+397.6% YoY
|
5.34M
5.34M – 5.34M
-99.8% YoY
|
| EBITDA |
-503.58M
est: -161.02M (-212.8%)
|
-168.20M
est: -35.70M (-371.1%)
|
-392.52M
est: 77.47M (-606.7%)
|
-290.29M
est: -28.29M (-926.2%)
|
-310.76M
-310.76M – -310.76M
-998.6% YoY
|
-435.09M
-435.09M – -435.09M
-40.0% YoY
|
-2.17B
-2.17B – -2.17B
-397.6% YoY
|
-5.34M
-5.34M – -5.34M
+99.8% YoY
|
| EBIT |
-513.85M
est: -161.02M (-219.1%)
|
-183.88M
est: -35.70M (-415.0%)
|
-399.50M
est: 77.47M (-615.7%)
|
-295.88M
est: -28.29M (-946.0%)
|
-310.76M
-310.76M – -310.76M
-998.6% YoY
|
-435.09M
-435.09M – -435.09M
-40.0% YoY
|
-2.17B
-2.17B – -2.17B
-397.6% YoY
|
-5.34M
-5.34M – -5.34M
+99.8% YoY
|
| Net Income |
-484.31M
est: -588.65M (+17.7%)
|
-174.83M
est: -244.43M (+28.5%)
|
-508.16M
est: -425.75M (-19.4%)
|
-216.86M
est: -187.61M (-15.6%)
|
-322.22M
-322.22M – -322.22M
-71.7% YoY
|
-314.72M
-314.72M – -314.72M
+2.3% YoY
|
-247.29M
-247.29M – -247.29M
+21.4% YoY
|
-239.79M
-239.79M – -239.79M
+3.0% YoY
|
| SGA |
80.33M
est: 250.86M (-68.0%)
|
57.10M
est: 91.35M (-37.5%)
|
203.94M
est: -198.23M (+202.9%)
|
101.67M
est: 72.38M (+40.5%)
|
795.16M
795.16M – 795.16M
+998.6% YoY
|
1.11B
1.11B – 1.11B
+40.0% YoY
|
5.54B
5.54B – 5.54B
+397.6% YoY
|
13.65M
13.65M – 13.65M
-99.8% YoY
|
| EPS |
-0.67
est: -0.81 (+16.9%)
|
-0.24
est: -0.34 (+29.1%)
|
-0.70
est: -0.59 (-18.7%)
|
-0.30
est: -0.26 (-15.4%)
|
-0.45
-0.45 – -0.45
-71.7% YoY
|
-0.44
-0.44 – -0.44
+2.3% YoY
|
-0.34
-0.34 – -0.34
+21.4% YoY
|
-0.33
-0.33 – -0.33
+3.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-14 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 67.1K | 0.65% |
| 2 | Avantis Responsible Emerging Markets Equity ETF AVSE | 0.00% | 6.9K | 0.33% |
| 3 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 95.0K | 0.33% |
| 4 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 410.74 | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Zhi Hong | Co-founder, Executive Chairman of the Board & Chief Executive Officer | 12M | — |
| Ankang Li | COO, Joint Secretary & Executive Director | 6M | — |
| David Margolis | Chief Medical Officer | — | — |
| Eleanor de Groot | Chief Technology Officer | — | — |
| Haifeng Cao | Head of China Development | — | male |
| Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | — | female |
| Qing Zhu | Head of Pre-clinical Sciences and Translational Research | — | — |
| Sarah Qiu | Associate Director of Investor Relations | — | — |
| Susannah Cantrell | Chief Business Officer | — | — |
| Wing Tsz FCIS | Joint Company Secretary | — | female |
| Brian Alvin Johns | Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2137.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
